Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy…
By M. Cristofanilli, N. Turner, I. Bondarenko, J. Ro, S. Im, N. Masuda, M. Colleoni, A. DeMichele, S. Loi, S. Verma and 8 more. The Lancet Oncology, 2016
1,507 citations recorded by the source corpus.
Subfields: Genetics, Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/5bf8096b3e1514406ad1ce451c9da2ef79e70c83
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Oncology
Citations in the corpus
- 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)† (2018, background): “In the second-line setting, their use has been associated with a 6–7 months progression-free survival (PFS) benefit [33, 34] and an HRQoL improvement [35, 36], and hence their ESMO-MCBS score is 4.”
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer (2018, neutral): “Gemcitabine 7 (3) 6 (3) 26 (20) 5 (4) 9 (8) 15 (18)”
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. (2021, background): “19 The imaging modality chosen at baseline should be applied for disease monitoring to ensure comparability [III, B].”
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. (2017, result): “Severe neutropenia has been frequently reported in phase III studies with other CDK 4 and 6 inhibitors and was a dose-limiting toxicity leading to the definition of intermittent dosing schedules.(5,6,28,29) This has not been the case in MONARCH 2 and other studies of abemaciclib, in which severe neu”